Visual fields measured with standard automated perimetry are a benchmark test for determining retinal function in ocular pathologies such as glaucoma. Their monitoring over time is crucial in detecting change in disease course and, therefore, in prompting clinical intervention and defining endpoints in clinical trials of new therapies. However, conventional change detection methods do not take into account non-stationary measurement variability or spatial correlation present in these measures. An inferential statistical model, denoted ‘Analysis with Non-Stationary Weibull Error Regression and Spatial enhancement’ (ANSWERS), was proposed. In contrast to commonly used ordinary linear regression models, which assume normally distributed errors, ANSWERS incorporates non-stationary variability modelled as a mixture of Weibull distributions. Spatial correlation of measurements was also included into the model using a Bayesian framework. It was evaluated using a large dataset of visual field measurements acquired from electronic health records, and was compared with other widely used methods for detecting deterioration in retinal function. ANSWERS was able to detect deterioration significantly earlier than conventional methods, at matched false positive rates. Statistical sensitivity in detecting deterioration was also significantly better, especially in short time series. Furthermore, the spatial correlation utilised in ANSWERS was shown to improve the ability to detect deterioration, compared to equivalent models without spatial correlation, especially in short follow-up series. ANSWERS is a new efficient method for detecting changes in retinal function. It allows for better detection of change, more efficient endpoints and can potentially shorten the time in clinical trials for new therapies.
References
[1]
Morgan JE (2012) Retina ganglion cell degeneration in glaucoma: an opportunity missed? A review. Clin Experiment Ophthalmol 40: 364–368.
[2]
Patel PJ, Chen FK, Da Cruz L, Rubin GS, Tufail A (2011) Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 52: 3089–3093.
[3]
Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, et al. (2008) Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358: 2231–2239.
[4]
Cramer AO, Maclaren RE (2013) Translating induced pluripotent stem cells from bench to bedside: application to retinal diseases. Curr Gene Ther 13: 139–151.
[5]
Guo L, Duggan J, Cordeiro MF (2010) Alzheimer's disease and retinal neurodegeneration. Curr Alzheimer Res 7: 3–14.
[6]
Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, et al. (2011) Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage 54: S204–217.
[7]
Oliveira C, Cestari DM, Rizzo JF (2012) The use of fourth-generation optical coherence tomography in multiple sclerosis: a review. Semin Ophthalmol 27: 187–191.
[8]
Trip SA, Schlottmann PG, Jones SJ, Altmann DR, Garway-Heath DF, et al. (2005) Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 58: 383–391.
[9]
McNeill A, Roberti G, Lascaratos G, Hughes D, Mehta A, et al. (2013) Retinal thinning in Gaucher disease patients and carriers: Results of a pilot study. Mol Genet Metab 109: 221–223.
[10]
Quigley HA, Broman AT (2006) The number of people with glaucoma worldwide in 2010 and 2020. British Journal of Ophthalmology 90: 262–267.
[11]
Pizzarello L, Abiose A, Ffytche T, Duerksen R, Thulasiraj R, et al. (2004) VISION 2020: The Right to Sight: a global initiative to eliminate avoidable blindness. Arch Ophthalmol 122: 615–620.
[12]
Viswanathan AC, Crabb DP, McNaught AI, Westcott MC, Kamal D, et al. (2003) Interobserver agreement on visual field progression in glaucoma: a comparison of methods. Br J Ophthalmol 87: 726–730.
[13]
Tanna AP, Bandi JR, Budenz DL, Feuer WJ, Feldman RM, et al. (2011) Interobserver agreement and intraobserver reproducibility of the subjective determination of glaucomatous visual field progression. Ophthalmology 118: 60–65.
[14]
Katz J, Gilbert D, Quigley HA, Sommer A (1997) Estimating progression of visual field loss in glaucoma. Ophthalmology 104: 1017–1025.
[15]
Smith SD, Katz J, Quigley HA (1996) Analysis of progressive change in automated visual fields in glaucoma. Invest Ophthalmol Vis Sci 37: 1419–1428.
[16]
Birch MK, Wishart PK, O'Donnell NP (1995) Determining progressive visual field loss in serial Humphrey visual fields. Ophthalmology 102: 1227–1234 discussion 1234–1225.
[17]
Chauhan BC, Drance SM, Douglas GR (1990) The use of visual field indices in detecting changes in the visual field in glaucoma. Invest Ophthalmol Vis Sci 31: 512–520.
[18]
Heijl A, Leske MC, Bengtsson B, Hussein M (2003) Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmol Scand 81: 286–293.
[19]
Artes PH (2008) Progression: things we need to remember but often forget to think about. Optom Vis Sci 85: 380–385.
[20]
Artes PH, Iwase A, Ohno Y, Kitazawa Y, Chauhan BC (2002) Properties of perimetric threshold estimates from Full Threshold, SITA Standard, and SITA Fast strategies. Invest Ophthalmol Vis Sci 43: 2654–2659.
[21]
Henson DB, Chaudry S, Artes PH, Faragher EB, Ansons A (2000) Response Variability in the Visual Field: Comparison of Optic Neuritis, Glaucoma, Ocular Hypertension, and Normal Eyes Invest Ophthalmol Vis Sci. 41: 417–421.
[22]
Russell RA, Crabb DP, Malik R, Garway-Heath DF (2012) The relationship between variability and sensitivity in large-scale longitudinal visual field data. Invest Ophthalmol Vis Sci 53: 5985–5990.
[23]
Garway-Heath DF, Poinoosawmy D, Fitzke FW, Hitchings RA (2000) Mapping the visual field to the optic disc in normal tension glaucoma eyes. Ophthalmology 107: 1809–1815.
[24]
Strouthidis NG, Vinciotti V, Tucker AJ, Gardiner SK, Crabb DP, et al. (2006) Structure and Function in Glaucoma: The Relationship between a Functional Visual Field Map and an Anatomic Retinal Map. Investigative Ophthalmology & Visual Science 47: 5356–5362.
[25]
Chauhan BC, Garway-Heath DF, Go？i FJ, Rossetti L, Bengtsson B, et al. (2008) Practical recommendations for measuring rates of visual field change in glaucoma. British Journal of Ophthalmology 92: 569–573.
[26]
Heijl A, Lindgren G, Olsson J (1989) The effect of perimetric experience in normal subjects. Arch Ophthalmol 107: 81–86.
[27]
Wild JM, Dengler-Harles M, Searle AE, O'Neill EC, Crews SJ (1989) The influence of the learning effect on automated perimetry in patients with suspected glaucoma. Acta Ophthalmol (Copenh) 67: 537–545.
[28]
Patterson AJ, Garway-Heath DF, Strouthidis NG, Crabb DP (2005) A New Statistical Approach for Quantifying Change in Series of Retinal and Optic Nerve Head Topography Images. Investigative Ophthalmology & Visual Science 46: 1659–1667.
[29]
Frackowiak RSJ (1997) Human Brain Function: Academic Press San Diego.
[30]
Dempster A, Laird N, Rubin D (1977) Maximum likelihood from incomplete data via the EM algorithm. Journal of the Royal Statistical Society 39(1): 1–38.
[31]
Tierney L, Kadane J (1986) Accurate approximations for posterior moments and marginal densities. Journal of the American Statistical Association 81: 82–86.
[32]
Bishop CM (1996) Neural network for pattern recognition. New York: Oxford University Press.
[33]
Gardiner SK, Crabb DP (2002) Examination of different pointwise linear regression methods for determining visual field progression. Invest Ophthalmol Vis Sci 43: 1400–1407.
[34]
Crabb DP, Fitzke FW, McNaught AI, Edgar DF, Hitchings RA (1997) Improving the prediction of visual field progression in glaucoma using spatial processing. Ophthalmology 104: 517–524.
[35]
Swift S, Liu X (2002) Predicting glaucomatous visual field deterioration through short multivariate time series modelling. Artif Intell Med 24: 5–24.
[36]
Strouthidis NG, Scott A, Viswanathan AC, Crabb DP, Garway-Heath DF (2007) Monitoring glaucomatous visual field progression: the effect of a novel spatial filter. Invest Ophthalmol Vis Sci 48: 251–257.
[37]
Tucker A, Vinciotti V, Liu X, Garway-Heath D (2005) A spatio-temporal Bayesian network classifier for understanding visual field deterioration. Artif Intell Med 34: 163–177.
[38]
Turin TC, Hemmelgarn BR (2011) Change in kidney function over time and risk for adverse outcomes: is an increasing estimated GFR harmful? Clin J Am Soc Nephrol 6: 1805–1806.
[39]
Rajendra Acharya U, Paul Joseph K, Kannathal N, Lim CM, Suri JS (2006) Heart rate variability: a review. Med Biol Eng Comput 44: 1031–1051.
[40]
Bogachev MI, Mamontov OV, Konradi AO, Uljanitski YD, Kantelhardt JW, et al. (2009) Analysis of blood pressure-heart rate feedback regulation under non-stationary conditions: beyond baroreflex sensitivity. Physiol Meas 30: 631–645.
[41]
Redmond T, Garway-Heath DF, Zlatkova MB, Anderson RS (2010) Sensitivity loss in early glaucoma can be mapped to an enlargement of the area of complete spatial summation. Invest Ophthalmol Vis Sci 51: 6540–6548.
[42]
Swanson WH, Felius J, Birch DG (2000) Effect of stimulus size on static visual fields in patients with retinitis pigmentosa. Ophthalmology 107: 1950–1954.
[43]
Malik R, Swanson WH, Garway-Heath DF (2006) Development and evaluation of a linear staircase strategy for the measurement of perimetric sensitivity. Vision Res 46: 2956–2967.
[44]
Westcott MC, Garway-Heath DF, Fitzke FW, Kamal D, Hitchings RA (2002) Use of high spatial resolution perimetry to identify scotomata not apparent with conventional perimetry in the nasal field of glaucomatous subjects. British Journal of Ophthalmology 86: 761–766.
[45]
Asaoka R, Russell RA, Malik R, Crabb DP, Garway-Heath DF (2012) A novel distribution of visual field test points to improve the correlation between structure-function measurements. Invest Ophthalmol Vis Sci 53: 8396–8404.
[46]
Harwerth RS, Carter-Dawson L, Shen F, Smith EL 3rd, Crawford ML (1999) Ganglion cell losses underlying visual field defects from experimental glaucoma. Invest Ophthalmol Vis Sci 40: 2242–2250.
